Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabcomeline SCHEMBL3133975 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3843721 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3838658 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133982 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7079710 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6392265 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL34463221 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL18049048 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629873 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629868 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | claimed |
| US-20180050008-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-12-29 | — | — | US | claimed |
| EP-0759921-B1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-07-09 | — | — | EP | claimed |
| EP-0759921-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031456-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-11-23 | — | — | WO | claimed |
| EP-4019018-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| US-10596139-B2 | Oxybutynin transdermal therapeutic system muscarinic agonist combination | CHASE PHARMACEUTICALS CORPORATION (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180250270-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180050008-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | disclosed |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2016-12-29 | — | — | US | disclosed |
| EP-0759921-B1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-07-09 | — | — | EP | disclosed |
| EP-0759920-B1 | DERIVATIVES OF QUINUCLIDINE N-OXIDE AS MUSCARINIC RECEPTOR LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-14 | — | — | EP | disclosed |
| EP-0759921-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-03-05 | — | — | EP | disclosed |
| EP-0759920-A1 | DERIVATIVES OF QUINUCLIDINE N-OXIDE AS MUSCARINIC RECEPTOR LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031456-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995031457-A1 | DERIVATIVES OF QUINUCLIDINE N-OXIDE AS MUSCARINIC RECEPTOR LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM4 3/4885CHRM1 7/4885 |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM4 3/4885CHRM1 5/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM4 3/4885CHRM1 5/4885 |
| US-20160375001-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM4 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.